Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Atzeni

Showing results (351-360 of 395) with videos related to

Pageof 40
Sort By:
Clinical and Experimental Rheumatology|May 17, 2022
Adult-onset Still's disease with elderly onset: results from a multicentre studyIlenia Di Cola, Claudia Di Muzio, Alessandro Conforti, et al.
Clinical and Experimental Rheumatology|January 10, 2024
Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experienceLidia La Barbera, Chiara Rizzo, Federica Camarda, et al.
Arthritis Research & Therapy|September 28, 2024
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohortRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Seminars in Arthritis and Rheumatism|October 2, 2022
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgiaBurak Kundakci, Michelle Hall, Fabiola Atzeni, et al.
Frontiers in Medicine|June 10, 2022
Early Spondyloarthritis Clinic: Organizational Improvements in the Patient JourneySalvatore D'Angelo, Antonella Afeltra, Fabiola Atzeni, et al.
Autoimmunity Reviews|July 17, 2012
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registryFabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, et al.
Annals of the Rheumatic Diseases|March 19, 2013
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre studyLuca Quartuccio, Martina Fabris, Elena Pontarini, et al.
Annals of the Rheumatic Diseases|November 3, 2022
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseasesGeorge E Fragoulis, Elena Nikiphorou, Mrinalini Dey, et al.
Arthritis and Rheumatism|September 25, 2012
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockersMartina Fabris, Luca Quartuccio, Ed Vital, et al.
Clinical and Experimental Rheumatology|May 4, 2023
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based studyFausto Salaffi, Marco Di Carlo, Manuela Di Franco, et al.
Pageof 40

Showing results (351-360 of 395) with videos related to

Sort By:
Pageof 40
Clinical and Experimental Rheumatology|May 17, 2022
Adult-onset Still's disease with elderly onset: results from a multicentre studyIlenia Di Cola, Claudia Di Muzio, Alessandro Conforti, et al.
Clinical and Experimental Rheumatology|January 10, 2024
Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experienceLidia La Barbera, Chiara Rizzo, Federica Camarda, et al.
Arthritis Research & Therapy|September 28, 2024
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohortRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Seminars in Arthritis and Rheumatism|October 2, 2022
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgiaBurak Kundakci, Michelle Hall, Fabiola Atzeni, et al.
Frontiers in Medicine|June 10, 2022
Early Spondyloarthritis Clinic: Organizational Improvements in the Patient JourneySalvatore D'Angelo, Antonella Afeltra, Fabiola Atzeni, et al.
Autoimmunity Reviews|July 17, 2012
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registryFabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, et al.
Annals of the Rheumatic Diseases|March 19, 2013
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre studyLuca Quartuccio, Martina Fabris, Elena Pontarini, et al.
Annals of the Rheumatic Diseases|November 3, 2022
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseasesGeorge E Fragoulis, Elena Nikiphorou, Mrinalini Dey, et al.
Arthritis and Rheumatism|September 25, 2012
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockersMartina Fabris, Luca Quartuccio, Ed Vital, et al.
Clinical and Experimental Rheumatology|May 4, 2023
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based studyFausto Salaffi, Marco Di Carlo, Manuela Di Franco, et al.
Pageof 40